Tempus AI Inc. (TEM)

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.

Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industrie...

There's no doubt about it. The technology sector has been a great place to invest for decades.

Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030, according to G...

Prior to the start of this week, Tempus AI (TEM -2.55%) stock had locked in a 161% gain since the start of the year -- an impressive performance for the healthcare company that's pioneering artificial...

TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearanc...

Tempus AI secures FDA clearance for its updated Pixel cardiac imaging platform, boosting radiology precision and efficiency.

Tempus AI stock price surged to a record high on Wednesday after the healthcare-focused artificial intelligence company announced a major breakthrough from the Food and Drug Administration (FDA). It j...